Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC3 | Q13489 | 3/20 | 0.34 |
| ▸ | XIAP | P98170 | 2/20 | 0.34 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.34 |
| ▸ | TERF2 | Q15554 | 6/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13685613 | 0.87 | TERF2 (0.34) | BIRC3XIAPBIRC2TERF2HDAC6 | |
| SCHEMBL13685682 | 0.74 | TERF2 (0.36) | BIRC3XIAPBIRC2TERF2NTSR1 | |
| SCHEMBL13685681 | 0.73 | TERF2 (0.34) | BIRC3XIAPBIRC2TERF2 | |
| SCHEMBL13685775 | 0.72 | HDAC1 (0.42) | BIRC3XIAPBIRC2TERF2HDAC6 | |
| SCHEMBL13685776 | 0.71 | TERF2 (0.41) | BIRC3XIAPBIRC2TERF2HDAC6 | |
| SCHEMBL13685773 | 0.68 | TERF2 (0.33) | BIRC3XIAPBIRC2TERF2HDAC6 | |
| SCHEMBL13685734 | 0.68 | TERF2 (0.32) | BIRC3XIAPBIRC2TERF2 | |
| SCHEMBL1645089 | 0.66 | F2 (0.37) | BIRC3XIAPBIRC2TERF2HDAC6 | |
| SCHEMBL13685777 | 0.66 | HDAC6 (0.33) | BIRC3XIAPBIRC2TERF2MMP3 | |
| SCHEMBL1655875 | 0.66 | BIRC3 (0.38) | BIRC3XIAPBIRC2TERF2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110150835-A1 | Macrocyclic Inhibitors of Hepatitis C Virus NS3 Serine Protease | SCHERING CORPORATION | 2011-06-23 | — | — | US | disclosed |
| EP-1664092-B1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORP (US) | 2011-02-02 | — | — | EP | disclosed |
| US-7592419-B2 | Macrocyclic inhibitors of hepatitis C virus NS3-serine protease | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592419-B2 | Macrocyclic inhibitors of hepatitis C virus NS3-serine protease | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| WO-2009058856-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2009-05-07 | — | — | WO | disclosed |
| WO-2005030796-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110150835-A1 | Macrocyclic Inhibitors of Hepatitis C Virus NS3 Serine Protease | TMPRSS15, SPINT2, HPN | BIRC3 193/4885XIAP 136/4885BIRC2 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.